Qiming Corporate Gp Vi, Ltd. (10% owner) sold $3.3M of stock
SEC Form 4
Alamar Biosciences, Inc. is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.
Stock price today
Loading chart…
Third-party market data · may be delayed
Model estimate per share
~$7.0
Valuation models combined (2)
Base case. Range ~$6.6–$8.3. Weighted average of 2 models (growth cash-flow model, forward price-to-sales vs peers), the growth cash-flow model counting double.
Price vs value
No Buy/Hold/Sell rating is issued: limited reported history: available models are shown without a Buy/Hold/Sell rating.
Alamar Biosciences, Inc. valuation: adjust assumptions and compare models →
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders2 buying, 1 selling2 purchases and 92 sales by directors and officers, last 12 monthsInsider trades
- Funds83 adding, 0 cuttingOf 23 active managers that changed their stake, 23 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 37% in the quarter to 2026-06-30.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Alamar Biosciences, Inc.'s latest figures clears our strength thresholds.
Things to watch
- Volatile shares. Over the past year the shares showed annualised volatility of 88% and a beta of 1.4 against the S&P 500.
- Short interest rising. Shares sold short rose 26% in a month to 6.2% of tradable shares.
Latest results
- Earnings per share
- -$0.20 against an average estimate of -$0.32: beat by 37.4%
- Share reaction
- +28.5% in the first session after the results on August 10, 2026, against -0.3% for the S&P 500
- Next report
- November 3, 2026; average EPS estimate -$0.19
Price chart
- 1 day-5.4%
- 1 week-4.8%
- 1 month-15.8%
Loading chart…
Third-party market data · may be delayed
At a glance
Earnings
- Last results
- August 10, 2026
News & updates
Company announcements, filed results and changes that matter to shareholders.
- Insider trade
- Insider trade
Qiming Corporate Gp Vi, Ltd. (10% owner) sold $2.7M of stock
SEC Form 4 - Leadership
Alamar Biosciences, Inc. announced a director or officer change
SEC 8-KRead source ↗ - Results
Alamar Biosciences, Inc. reported results
SEC 8-KRead source ↗ - Announcement
Alamar Biosciences, Inc. disclosed a material event
SEC 8-KRead source ↗
Valuation models
We value Alamar Biosciences, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.6%: the 10-year Treasury yield (4.9%) plus a beta of 1.04 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. | ~$6.6 ~$4.7–$8.2 | Primary model, counts double |
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. | ~$8.3 ~$6.8–$17 | Included, half weight |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | ~$7.0 ~$6.6–$8.3 | 2 models |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Alamar Biosciences, Inc. with Life Sciences Tools & Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Next results: November 3, 2026, after the close. Analysts expect revenue of $30m and EPS of −$0.19 (range −$0.26 to −$0.10) for the quarter.
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$1.10 | — | $119m | — |
| Next | −$0.45 | +59% | $166m | +40% |
How the EPS forecast has moved
The consensus EPS forecast for the current fiscal year is −24.4% on 90 days ago. In the last 30 days, 4 analysts raised Alamar Biosciences, Inc.'s forecast and 0 cut it.
Average of analysts' published estimates (third-party data).
View chart data
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$1.46 | −$0.70 |
| 60 days ago | −$1.16 | −$0.54 |
| 30 days ago | −$1.16 | −$0.54 |
| 7 days ago | −$1.16 | −$0.54 |
| Now | −$1.10 | −$0.45 |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.32 | −$0.20 | +37.4% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 6.3% of tradable shares
- Days to cover
- 3.53 at average volume
- Short interest, 1 month
- +26% to October 15, 2026
- Held by institutions
- 57% of shares
- Held by insiders
- 22.2% of shares
- Employees
- 286 full time
Share-price performance
Market data may be delayedPrice behaviour
- 52-week range
- Not enough history
- From 52-week high
- —
- vs 50-day average
- −5.2%
- vs 200-day average
- —
- Volatility (1 year)
- 88%
- Beta vs S&P 500
- 1.39
Share price after results
- Next day
- 2 up, 0 down typical move ±14.7%
- After a week
- 1 up, 1 down typical move ±10.9%
- After a month
- 1 up, 1 down typical move ±8.3%
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 10, 2026 | +28.5% | −0.3% | +12.9% | +1.8% |
| May 8, 2026 | +0.9% | +1.1% | −9.0% | −14.9% |
Fundamentals
Who owns it
Funds buying and selling- Reported value
- $660M
- Institutions reporting
- 86
- Positions opened / closed
- 83 / 0
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Sands Capital Alternatives, LLC | $115M | 4.2M | 17.4% | — |
| Samsara Biocapital, LLC | $67.2M | 2.5M | 10.2% | — |
| T. Rowe Price Investment Management, Inc. | $59.7M | 2.2M | 9.0% | — |
| ARK Investment Management LLC | $37.2M | 1.4M | 5.6% | — |
| Braidwell LP | $29.4M | 1.1M | 4.4% | — |
| Alliancebernstein L.P. | $27.2M | 1.0M | 4.1% | — |
| Hhlr Advisors, Ltd. | $25.9M | 956K | 3.9% | — |
| Blackrock, Inc. | $24.7M | 911K | 3.7% | — |
| Millennium Management LLC | $23.5M | 866K | 3.6% | — |
| FMR LLC | $22.5M | 829K | 3.4% | — |
| Pura Vida Investments, LLC | $20.5M | 756K | 3.1% | — |
| Emerald Advisers, LLC | $17.5M | 647K | 2.7% | — |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Alamar Biosciences, Inc.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chart Insider purchases History → $8M 2 trades by 2 insiders, last 12 months Insider sales History → $35.6M 92 trades by 1 insider · 0% under pre-set plans
Net ▼ $27.6M net selling
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Qiming Corporate Gp Vi, Ltd. 10% owner | October 28, 2026 | Sell | 8,450 | $33.11 | $279,780 |
| Qiming Corporate Gp Vi, Ltd. 10% owner | October 28, 2026 | Sell | 9,846 | $32.47 | $319,700 |
| Qiming Corporate Gp Vi, Ltd. 10% owner | October 28, 2026 | Sell | 7,058 | $33.11 | $233,690 |
| Qiming Corporate Gp Vi, Ltd. 10% owner | October 28, 2026 | Sell | 8,224 | $32.47 | $267,033 |
| Qiming Corporate Gp Vi, Ltd. 10% owner | October 28, 2026 | Sell | 30,249 | $33.11 | $1M |
| Qiming Corporate Gp Vi, Ltd. 10% owner | October 28, 2026 | Sell | 35,248 | $32.47 | $1.1M |
| Qiming Corporate Gp Vi, Ltd. 10% owner | October 28, 2026 | Sell | 814 | $33.11 | $26,952 |
| Qiming Corporate Gp Vi, Ltd. 10% owner | October 28, 2026 | Sell | 948 | $32.47 | $30,782 |
| Qiming Corporate Gp Vi, Ltd. 10% owner | October 27, 2026 | Sell | 4,226 | $31.88 | $134,725 |
| Qiming Corporate Gp Vi, Ltd. 10% owner | October 27, 2026 | Sell | 9,791 | $31.33 | $306,752 |
| Qiming Corporate Gp Vi, Ltd. 10% owner | October 27, 2026 | Sell | 1,386 | $30.33 | $42,037 |
| Qiming Corporate Gp Vi, Ltd. 10% owner | October 27, 2026 | Sell | 3,531 | $31.88 | $112,568 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
- August 10, 2026
- May 8, 2026
Recent SEC filings
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- S-1 S-1
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Alamar Biosciences, Inc. in brief
- What does Alamar Biosciences, Inc. do?
- Alamar Biosciences, Inc. is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.
- What is Alamar Biosciences, Inc.'s stock ticker?
- Alamar Biosciences, Inc. trades under the ticker ALMR on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Alamar Biosciences, Inc.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Sands Capital Alternatives, LLC, Samsara Biocapital, LLC and T. Rowe Price Investment Management, Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- Are insiders buying or selling Alamar Biosciences, Inc. stock?
- Over the last 12 months, Alamar Biosciences, Inc.'s directors and officers reported 2 open-market purchases and 92 sales on Form 4. The insider trading page charts every trade.
- When is Alamar Biosciences, Inc.'s next earnings date?
- Around November 3, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Alamar Biosciences, Inc. announces its own schedule.
Follow research on Alamar Biosciences, Inc.
New research on the companies we cover arrives in the weekly email. Free, one email a week.